ArticleTurkish journal of obstetrics and gynecology2018
Visfatin as a predictor for growth of fetus and infant.
Article in Turkish journal of obstetrics and gynecology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 9 citations in OpenAlex.
- Impact of Gestational Diabetes Mellitus on Fetal Growth and Nutritional Status in Newborns.Nutrients · 2024Review
- Novel Biomolecules in the Pathogenesis of Gestational Diabetes Mellitus.International journal of molecular sciences · 2021Review
- The Role of the Adipokines in the Most Common Gestational Complications.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveVisfatin is an adipocytokine that functions as an enzyme and a growth factor to investigate the relationship between serum visfatin and the fetus's anthropometric markers up to a year after birth. MATERIALS AND
methodsForty-one eligible pregnant women in their first trimester were divided and matched in terms of body mass index (BMI) before pregnancy into normal and higher than normal BMI groups, A and B. Serum visfatin levels were measured during 6-12 and 15-20 weeks of gestation using ELISA.
resultsThe infants were followed up for a mean duration of 10.19±2.83 months. In group A, there was a strong positive relationship between birth head circumference and the first (p
conclusionMaternal serum visfatin level shows a relationship with fetal and infant anthropometric indicators, with different effects in the two groups, suggesting visfatin dysfunction in the overweight group before pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.